The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
May 9th 2024
Pembrolizumab has existing indications in endometrial cancer.
ASCO Spotlight With Kim A. Reiss, MD, on CAR Macrophages and Other Developments in Pancreatic Cancer
July 21st 2022Kim A. Reiss, MD, assistant program director, assistant professor of medicine, Hospital of the University of Pennsylvania, Philadelphia, discusses 2 abstracts presented during ASCO.
Read More
Patients With Cancer Face Major Financial Roadblocks, Not All Concerning Out-of-Pocket Costs
July 7th 2022Abstracts presented at this year's American Society of Clinical Oncology Annual meeting detailed the financial hardships many patients with cancer face, including those related to high-deductible health plans and clinical trial participation.
Read More
Dr Zahra Mahmoudjafari Explains How Payers Can Better Manage CAR T Costs, Increase Access
July 2nd 2022Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.
Watch
COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”
June 23rd 2022Miruna Sasu, PhD, MBA, became president and CEO of COTA Healthcare in March 2022, not quite a year after joining the company as its chief strategy officer. As the importance of RWD grows, Sasu is ready to take its use in precision oncology to new levels. She spoke with Evidence-Based Oncology™ (EBO) about her new role.
Read More
Major Adverse Cardiac Events Related to ICI Treatment Explored in New Study
June 17th 2022Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.
Read More
Cardinal Health’s Aklilu Tedla on CAR T-Cell Administration Outside of the Hospital
June 8th 2022Moving chimeric antigen receptor (CAR) T-cell therapies outside of the hospital will bring training and safety challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Watch
Cardinal Health’s Aklilu Tedla Discusses Logistics of Allogeneic CAR T-Cell Therapies
May 31st 2022Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Watch
Review Highlights Tumor Microenvironment Features Contributing to Immunotherapy Resistance
May 20th 2022Treatment resistance is a significant challenge in immunotherapy, but it is not fully understood. A recent review summarized 5 tumor microenvironment traits that may inhibit therapy effectiveness and potential strategies to improve therapy responses.
Read More
Pressure-Induced Increase in PD-L1 Expression May Dull Effect of CAR T-Cell Therapy
May 10th 2022The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also suggest that adding PD-1/PD-L1 inhibitors to CAR T-cell therapy could help address this.
Read More
NCCN Recommends Pacritinib for Treatment of Myeloproliferative Neoplasms
April 18th 2022Pacritinib is now included as a recommended treatment for myeloproliferative neoplasms with specificity for JAK2 and IRAK1 in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.
Read More
Evidence, Support, and Education Needed to Drive Precision Oncology, Accenture’s Bogdan Says
April 14th 2022Accenture’s 2021 report, “The Future Is Now: How to Drive Precision Oncology Adoption," adds to the chorus calling for greater sharing of data and improved standardization, so that academic centers and community practices alike can continually improve data sets used worldwide.
Read More
AstraZeneca’s Camille Hertzka Addresses rPFS in mCRPC
April 12th 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.
Watch
Study Finds LCOR May Be a Viable Target to Increase Efficacy of Immunotherapy in TNBC
April 8th 2022Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.
Read More
AstraZeneca’s Camille Hertzka: Olaparib Could Be Practice Changing
April 1st 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why so much excitement has been generated for the use of olaparib (Lynparza) in the first line for patients with metastatic castrate-resistant prostate cancer.
Watch
Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL
March 19th 2022Mantle cell lymphoma is a difficult cancer type with high relapse rates, but novel targeted approaches such as CAR T-cell therapy hold promise for more successful response rates in the future.
Read More
CAR T-Cell Therapy in Hematological Cancers: Current Challenges and Future Potential
March 6th 2022Although chimeric antigen receptor (CAR) T-cell treatments have shown efficacy in certain cancers, targeting multiple antigens and overcoming production limitations may advance the field and make this therapy more effective and accessible.
Read More